Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|23|7|1119-1124

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.7, 2017-04, pp. : 1119-1124

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peroxisome Proliferator-Activated Receptor Agonists as Potential Therapeutic Agents in Multiple Sclerosis

By  

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 11, 2007-11 ,pp. : 1129-1135

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor-&ggr; (PPAR-&ggr;) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk

By  

Current Molecular Pharmacology, Vol. 5, Iss. 2, 2012-01 ,pp. : 272-281

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome proliferator-activated receptor ligands in atherosclerosis

By Viles-Gonzalez Juan F   Choi Brian G   Fuster Valentin   Badimon Juan J  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1393-1403

Informa Healthcare

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence

By  

Current Drug Targets, Vol. 14, Iss. 7, 2013-06 ,pp. : 768-776

Bentham Science Publishers

Access to resources Recommend Favorite

Enantioselective Synthesis of PPAR (Peroxisome Proliferator-Activated Receptors) Agonists and Antagonists

By  

Current Topics in Medicinal Chemistry, Vol. 14, Iss. 10, 2014-05 ,pp. : 1283-1293

Bentham Science Publishers

Access to resources Recommend Favorite